Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed

Indication
Primary Immune Thrombocytopenia (ITP)

Other upcoming events for ARGX

Phase 1 StartPhase 1 Start: An Open-Label, Single-Arm, Phase 1b Study to Evaluate the Effect of Empasiprubart on Nerve Morpholog
Phase 2 StartPhase 2 Start: A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the
Phase 2 StartPhase 2 Start: A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the
Phase 3 ReadoutPhase 3 Topline: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Ac
Phase 3 ReadoutPhase 3 Topline: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Ac

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed — ARGX Phase 3 Readout | BioSniper